Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial

BACKGROUND: High-dose intravenous immunoglobulin (IVIG) is the mainstay of treatment for Kawasaki disease (KD). Usually, 2 g/kg of IVIG is administered over 10–24 h, depending on the institution or physician, but the association between infusion speed and effectiveness has not been reported. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukui, Saori, Seki, Mitsuru, Minami, Takaomi, Kotani, Kazuhiko, Oka, Kensuke, Yokomizo, Akiko, Matsubara, Daisuke, Sato, Tomoyuki, Nozaki, Yasuyuki, Saito, Mari, Kikuchi, Yutaka, Miyamoto, Kenji, Monden, Yukifumi, Yamagata, Takanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254926/
https://www.ncbi.nlm.nih.gov/pubmed/34217297
http://dx.doi.org/10.1186/s12969-021-00601-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254926/
https://www.ncbi.nlm.nih.gov/pubmed/34217297
http://dx.doi.org/10.1186/s12969-021-00601-6

Ejemplares similares